Antibe Therapeutics Inc. – TSX:ATE.TO

Founder-led company

Antibe Therapeutics stock price today

CAD 0.66
+0.36
+123.73%
Financial Health
0
1
2
3
4
5
6
7
8
9

Antibe Therapeutics stock price quarterly change

-69.59%
quarter

Antibe Therapeutics stock price yearly change

-46.36%
year

Antibe Therapeutics key metrics

Market Cap
 15.63M
Enterprise value
 N/A
P/E
 -1.42
EV/Sales
 N/A
EV/EBITDA
 N/A
Price/Sales
 N/A
Price/Book
 0.65
PEG ratio
 -0.36
EPS
 -0.35
Revenue
 N/A
EBITDA
 -18.60M
Income
 -18.55M
Revenue Q/Q
 N/A
Revenue Y/Y
 N/A
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 N/A

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Antibe Therapeutics stock price history

Antibe Therapeutics stock forecast

Antibe Therapeutics financial statements

Profit Margin

Antibe Therapeutics Inc. (TSX:ATE.TO): Profit margin
Mar 2023 0 -3.54M
Jun 2023 0 -5.78M
Sep 2023 0 -5.00M
Dec 2023 0 -4.21M
ATE.TO income statement history

Antibe Therapeutics Financials Estimate

Antibe Therapeutics Inc. (TSX:ATE.TO): Analyst Estimates
2028 16.62M -4.18M -25.15%

  • Analysts Price target

  • Financials & Ratios estimates

Show more

Debt to Assets

Antibe Therapeutics Inc. (TSX:ATE.TO): Debt to assets
Dec 2022 73729000 30.46M 41.32%
Jun 2023 66837000 32.04M 47.94%
Sep 2023 60205000 30.49M 50.65%
Dec 2023 56362000 30.42M 53.98%
ATE.TO balance sheet history

Cash Flow

Antibe Therapeutics Inc. (TSX:ATE.TO): Cash Flow
Mar 2023 -3.38M -549K 159K
Jun 2023 -4.58M 6.62M 0
Sep 2023 -6.43M 1.78M 0
Dec 2023 -3.84M 11.04M 0
ATE.TO cash flow history

Antibe Therapeutics alternative data

Antibe Therapeutics
Employees

Antibe Therapeutics Inc. (TSX:ATE.TO): Employee count
Aug 2023 11
Sep 2023 11
Oct 2023 11
Nov 2023 11
Dec 2023 11
Jan 2024 11
Feb 2024 11
Mar 2024 11
Apr 2024 11
May 2024 11
Jun 2024 11
Jul 2024 11

Antibe Therapeutics other data

Antibe Therapeutics
Executives

Insider Compensation
Dr. Joseph Stauffer (1966) Chief Medical Officer $529,170
Dr. John Lawrence Wallace M.B.A., M.Sc., MBA, MSc, Ph.D. (1957) Founder, Chief Scientific Officer & Director
 $481,610
Mr. Daniel Marcel Legault J.D., L.L.B. (1958) Pres, Chief Executive Officer, Sec. & Director
 $481,610
Dr. David James Vaughan (1950) Chief Devel. Officer
 $303,340

Frequently Asked Questions (FAQ)

  • What's the price of Antibe Therapeutics stock today?

    One share of Antibe Therapeutics stock can currently be purchased for approximately $0.66.

  • When is Antibe Therapeutics's next earnings date?

    Unfortunately, Antibe Therapeutics's (ATE.TO) next earnings date is currently unknown.

  • Does Antibe Therapeutics pay dividends?

    No, Antibe Therapeutics does not pay dividends.

  • How much money does Antibe Therapeutics make?

    Antibe Therapeutics has a market capitalization of 15.63M.

  • What is Antibe Therapeutics's stock symbol?

    Antibe Therapeutics Inc. is traded on the TSX under the ticker symbol "ATE.TO".

  • What is Antibe Therapeutics's primary industry?

    Company operates in the Healthcare sector and Medical - Devices industry.

  • How do i buy shares of Antibe Therapeutics?

    Shares of Antibe Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Antibe Therapeutics's key executives?

    Antibe Therapeutics's management team includes the following people:

    • Dr. Joseph Stauffer Chief Medical Officer(age: 59, pay: $529,170)
    • Dr. John Lawrence Wallace M.B.A., M.Sc., MBA, MSc, Ph.D. Founder, Chief Scientific Officer & Director(age: 68, pay: $481,610)
    • Mr. Daniel Marcel Legault J.D., L.L.B. Pres, Chief Executive Officer, Sec. & Director(age: 67, pay: $481,610)
    • Dr. David James Vaughan Chief Devel. Officer(age: 75, pay: $303,340)

  • Is Antibe Therapeutics founder-led company?

    Yes, Antibe Therapeutics is a company led by its founder Dr. John Lawrence Wallace M.B.A., M.Sc., MBA, MSc, Ph.D..

  • How many employees does Antibe Therapeutics have?

    As Jul 2024, Antibe Therapeutics employs 11 workers.

  • When Antibe Therapeutics went public?

    Antibe Therapeutics Inc. is publicly traded company for more then 12 years since IPO on 18 Jun 2013.

  • What is Antibe Therapeutics's official website?

    The official website for Antibe Therapeutics is antibethera.com.

  • Where are Antibe Therapeutics's headquarters?

    Antibe Therapeutics is headquartered at 15 Prince Arthur Avenue, Toronto, ON.

  • How can i contact Antibe Therapeutics?

    Antibe Therapeutics's mailing address is 15 Prince Arthur Avenue, Toronto, ON and company can be reached via phone at +41 69223460.

Antibe Therapeutics company profile:

Antibe Therapeutics Inc.

antibethera.com
Exchange:

TSX

Full time employees:

11

Industry:

Medical - Devices

Sector:

Healthcare

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. Its lead compound is Otenaproxesul, a hydrogen sulfide-releasing derivative of naproxen for treating post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout that has completed Phase 2B gastrointestinal safety study. In addition, the company's products comprise ATB-352, which is in preclinical stage for acute pain. Antibe Therapeutics Inc. was incorporated in 2009 and is headquartered in Toronto, Canada.

+41 69223460
15 Prince Arthur Avenue
Toronto, ON M5R 1B2

:
ISIN: CA0370255097
: